William J Aronson

Title(s)Professor-in-Residence, Urology
SchoolMedicine
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Role of GPR120 and Macrophages in Dietary Omega-3 Fatty Acid Inhibition of Prostate Cancer
    NIH R01CA231219Sep 17, 2018 - Aug 31, 2023
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Addressing racial disparities in prostate cancer pathology prediction models: external validation and comparison of four models of pathological outcome prediction before radical prostatectomy in the multiethnic SEARCH cohort. Prostate Cancer Prostatic Dis. 2024 Apr 11. Mottaghi M, Gu L, Deivasigamani S, Adams ES, Parrish J, Amling CL, Aronson WJ, Kane CJ, Terris MK, Guerrios-Rivera L, Cooperberg MR, Klaassen Z, Freedland SJ, Polascik TJ. PMID: 38605270.
      View in: PubMed   Mentions:
    2. Systemic and Tumor-directed Therapy for Oligometastatic Prostate Cancer: The SOLAR Phase 2 Trial in De Novo Oligometastatic Prostate Cancer. Eur Urol. 2024 Mar 14. Nickols NG, Tsai S, Kane N, Tran S, Ghayouri L, Diaz-Perez S, Thein M, Anderson-Berman N, Eason J, Kishan AU, Steinberg ML, Reiter RE, Lee SP, Gin GE, Kwon R, Chang MG, Chao HH, Solanki AA, Sexton R, Lewis M, Lorentz W, Cheung MK, Gage DL, Duriseti S, Valle L, Berenji G, Aronson WJ, Garraway IP, Rettig MB. PMID: 38490853.
      View in: PubMed   Mentions:    Fields:    
    3. Do Hispanic Puerto Rican men have worse outcomes after radical prostatectomy? Results from SEARCH. Cancer Med. 2024 Feb; 13(4):e7012. Guerrios-Rivera L, Janes JL, De Hoedt AM, Klaassen Z, Terris MK, Cooperberg MR, Amling CL, Kane CJ, Aronson WJ, Fowke JH, Freedland SJ. PMID: 38457188; PMCID: PMC10922022.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    4. Effect of omega-3 fatty acid diet on prostate cancer progression and cholesterol efflux in tumor-associated macrophages-dependence on GPR120. Prostate Cancer Prostatic Dis. 2023 Oct 23. Liang P, Henning SM, Grogan T, Elashoff D, Said J, Cohen P, Aronson WJ. PMID: 37872251.
      View in: PubMed   Mentions: 1     Fields:    
    5. Diabetes and Prostate Cancer Outcomes in Men with Nonmetastatic Castration-Resistant Prostate Cancer: Results from the SEARCH Cohort. Cancer Epidemiol Biomarkers Prev. 2023 09 01; 32(9):1208-1216. Sergeyev A, Gu L, De Hoedt AM, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Klaassen Z, Terris MK, Guerrios-Rivera L, Freedland SJ, Csizmadi I. PMID: 37294698; PMCID: PMC10529387.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    6. Are associations between obesity and prostate cancer outcomes following radical prostatectomy the same in smokers and non-smokers? Results from the SEARCH Cohort. Cancer Causes Control. 2023 Nov; 34(11):983-993. Liu IT, Gu L, De Hoedt AM, Cooperberg MR, Amling CL, Kane CJ, Klaassen Z, Terris MK, Guerrios-Rivera L, Vidal AC, Aronson WJ, Freedland SJ, Csizmadi I. PMID: 37405681.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    7. Time from biopsy to radical prostatectomy by race in an equal-access healthcare system: Results from the SEARCH cohort. Prostate. 2023 Aug; 83(11):1011-1019. Pereira V, Oyekunle T, Janes J, Amling CJ, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Klaassen Z, Freedland SJ, Vidal AC, Csizmadi I. PMID: 37096737.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    8. A modeling study to estimate prostate cancer-specific mortality on active surveillance for men with favorable intermediate-risk prostate cancer: Results from the SEARCH cohort. Cancer Med. 2023 05; 12(9):10931-10938. Kuhlmann PK, Oyekunle T, Klaassen Z, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ. PMID: 37031461; PMCID: PMC10225172.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    9. Impact of darolutamide on local symptoms: pre-planned and post hoc analyses of the ARAMIS trial. BJU Int. 2023 04; 131(4):452-460. Shore ND, Stenzl A, Pieczonka C, Klaassen Z, Aronson WJ, Karsh L, Ryan CJ, Ortiz J, Srinivasan S, Mohamed AF, Verholen F. PMID: 36087070.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    10. Is time to castration resistant prostate cancer a potential intermediate end-point for time to metastasis among men initiating androgen deprivation therapy for non-metastatic prostate cancer with rapid PSA doubling time (<9 months)? Prostate Cancer Prostatic Dis. 2023 03; 26(1):151-155. Klaassen Z, Howard L, Wallis CJD, Janes JL, De Hoedt A, Aronson WJ, Polascik TJ, Amling CJ, Kane CJ, Cooperberg MR, Terris MK, Wu Y, Freedland SJ. PMID: 36050455.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    11. Reply by Authors. Urol Pract. 2022 Sep; 9(5):413. Taich L, Zhao H, Stock SR, Howard LE, De Hoedt AM, Terris MK, Amling CL, Kane CJ, Cooperberg MR, Aronson WJ, Klaassen Z, Polascik TJ, Vidal AC, Freedland SJ. PMID: 37145765.
      View in: PubMed   Mentions:
    12. Radium-223 Utilization Patterns and Outcomes in Clinical Practice. Urol Pract. 2022 Sep; 9(5):405-413. Taich L, Zhao H, Stock SR, Howard LE, De Hoedt AM, Terris MK, Amling CL, Kane CJ, Cooperberg MR, Aronson WJ, Klaassen Z, Polascik TJ, Vidal AC, Freedland SJ. PMID: 37145712.
      View in: PubMed   Mentions:
    13. Red Blood Cell Distribution Width Is Associated with All-cause Mortality but Not Adverse Cancer-specific Outcomes in Men with Clinically Localized Prostate Cancer Treated with Radical Prostatectomy: Findings Based on a Multicenter Shared Equal Access Regional Cancer Hospital Registry. Eur Urol Open Sci. 2022 Mar; 37:106-112. Orabi H, Howard L, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Klaassen Z, Janes JL, Freedland SJ, Polascik TJ. PMID: 35243395; PMCID: PMC8883186.
      View in: PubMed   Mentions: 3  
    14. Effects of dietary omega-3 fatty acids on orthotopic prostate cancer progression, tumor associated macrophages, angiogenesis and T-cell activation-dependence on GPR120. Prostate Cancer Prostatic Dis. 2022 09; 25(3):539-546. Liang P, Henning SM, Grogan T, Elashoff D, Ye H, Cohen P, Aronson WJ. PMID: 35075215; PMCID: PMC9308823.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    15. Prostate weight and prostate cancer outcomes after radical prostatectomy: Results from the SEARCH cohort study. Prostate. 2022 02; 82(3):366-372. Barlow SK, Oyekunle T, Janes JL, De Hoedt AM, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Klaassen ZW, Terris MK, Freedland SJ, Csizmadi I. PMID: 34905632.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    16. Corrigendum to "Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT)" [Eur Urol 77 (2020) 713-24]. Eur Urol. 2022 Feb; 81(2):e52. Wilt TJ, Vo TN, Langsetmo L, Dahm P, Wheeler T, Aronson WJ, Cooperberg MR, Taylor BC, Brawer MK. PMID: 34836682.
      View in: PubMed   Mentions: 1     Fields:    
    17. Association between Delay to Radical Prostatectomy and Clinically Meaningful Outcomes among Patients with Intermediate and High-Risk Localized Prostate Cancer. J Urol. 2022 03; 207(3):592-600. Lee MC, Erickson TR, Stock S, Howard LE, De Hoedt AM, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Klaassen Z, Freedland SJ, Wallis CJD. PMID: 34694910.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    18. Safety of concomitant therapy with radium-223 and abiraterone or enzalutamide in a real-world population. Prostate. 2021 05; 81(7):390-397. Zhao H, Howard LE, De Hoedt AM, Terris MK, Amling CL, Kane CJ, Cooperberg MR, Aronson WJ, Klaassen Z, Polascik TJ, Vidal AC, Freedland SJ. PMID: 33705584.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    19. Diabetes and Prostate Cancer Outcomes in Obese and Nonobese Men After Radical Prostatectomy. JNCI Cancer Spectr. 2021 06; 5(3). Kelkar S, Oyekunle T, Eisenberg A, Howard L, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Klaassen Z, Terris MK, Freedland SJ, Csizmadi I. PMID: 34169227; PMCID: PMC8220304.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    20. Is body composition linked to prostate cancer survival? Nat Rev Urol. 2021 03; 18(3):135-136. Csizmadi I, Aronson WJ. PMID: 33442050.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    21. Monocyte counts and prostate cancer outcomes in white and black men: results from the SEARCH database. Cancer Causes Control. 2021 Feb; 32(2):189-197. Yirga A, Oyekunle T, Howard LE, De Hoedt AM, Cooperberg MR, Kane CJ, Aronson WJ, Terris MK, Amling CL, Taioli E, Fowke JH, Klaanssen Z, Freedland SJ, Vidal AC. PMID: 33392907; PMCID: PMC7856261.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    22. Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate. JAMA Oncol. 2020 12 01; 6(12):1912-1920. Dess RT, Suresh K, Zelefsky MJ, Freedland SJ, Mahal BA, Cooperberg MR, Davis BJ, Horwitz EM, Terris MK, Amling CL, Aronson WJ, Kane CJ, Jackson WC, Hearn JWD, Deville C, DeWeese TL, Greco S, McNutt TR, Song DY, Sun Y, Mehra R, Kaffenberger SD, Morgan TM, Nguyen PL, Feng FY, Sharma V, Tran PT, Stish BJ, Pisansky TM, Zaorsky NG, Moraes FY, Berlin A, Finelli A, Fossati N, Gandaglia G, Briganti A, Carroll PR, Karnes RJ, Kattan MW, Schipper MJ, Spratt DE. PMID: 33090219; PMCID: PMC7582232.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    23. Do Hispanic Men Have Worse Outcomes After Radical Prostatectomy? Results From SEARCH. Urology. 2021 03; 149:181-186. Guerrios-Rivera L, Howard LE, Klaassen Z, Terris MK, Cooperberg MR, Amling CL, Kane CJ, Aronson WJ, Freedland SJ. PMID: 33189734.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    24. The Impact of Comorbidity and Age on Timing of Androgen Deprivation Therapy in Men with Biochemical Recurrence after Radical Prostatectomy. Urol Pract. 2021 Mar; 8(2):238-245. Moradzadeh A, Howard LE, Freedland SJ, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Klaassen Z, Terris MK, Daskivich TJ. PMID: 37145618.
      View in: PubMed   Mentions:
    25. Obese men undergoing radical prostatectomy: Is robotic or retropubic better to limit positive surgical margins? Results from SEARCH. Int J Urol. 2020 10; 27(10):851-857. Nik-Ahd F, Howard LE, Aronson WJ, Terris MK, Klaassen Z, Cooperberg MR, Amling CL, Kane CJ, Freedland SJ. PMID: 32681540.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    26. Obesity, race, and long-term prostate cancer outcomes. Cancer. 2020 08 15; 126(16):3733-3741. Vidal AC, Oyekunle T, Howard LE, De Hoedt AM, Kane CJ, Terris MK, Cooperberg MR, Amling CL, Klaassen Z, Freedland SJ, Aronson WJ. PMID: 32497282.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    27. Race does not predict skeletal-related events and all-cause mortality in men with castration-resistant prostate cancer. Cancer. 2020 07 15; 126(14):3274-3280. Patel DN, Howard LE, De Hoedt AM, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Klaassen ZW, Terris MK, Freedland SJ. PMID: 32374476.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    28. Prospective randomized trial evaluating blood and prostate tissue concentrations of green tea polyphenols and quercetin in men with prostate cancer. Food Funct. 2020 May 01; 11(5):4114-4122. Henning SM, Wang P, Lee RP, Trang A, Husari G, Yang J, Grojean EM, Ly A, Hsu M, Heber D, Grogan T, Li Z, Aronson WJ. PMID: 32347270; PMCID: PMC8312236.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    29. Competing Risks of Mortality among Men with Biochemical Recurrence after Radical Prostatectomy. J Urol. 2020 Sep; 204(3):511-517. Daskivich TJ, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Klaassen Z, Terris MK, Freedland SJ. PMID: 32243242.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    30. Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT). Eur Urol. 2020 06; 77(6):713-724. Wilt TJ, Vo TN, Langsetmo L, Dahm P, Wheeler T, Aronson WJ, Cooperberg MR, Taylor BC, Brawer MK. PMID: 32089359.
      View in: PubMed   Mentions: 42     Fields:    Translation:Humans
    31. Reply by Authors. J Urol. 2020 01; 203(1):127. Dambal S, Howard LE, Allott EH, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Freedland SJ. PMID: 31609668.
      View in: PubMed   Mentions:    Fields:    
    32. Racial Discrepancies in Overall Survival among Men Treated with 223Radium. J Urol. 2020 02; 203(2):331-337. Zhao H, Howard LE, De Hoedt A, Terris MK, Amling CL, Kane CJ, Cooperberg MR, Aronson WJ, Klaassen Z, Polascik TJ, Vidal AC, Freedland SJ. PMID: 31479407.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    33. Effect of dietary omega-3 fatty acids on castrate-resistant prostate cancer and tumor-associated macrophages. Prostate Cancer Prostatic Dis. 2020 03; 23(1):127-135. Liang P, Henning SM, Guan J, Grogan T, Elashoff D, Cohen P, Aronson WJ. PMID: 31439889; PMCID: PMC7031053.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsCells
    34. Serum Lipids prior to Starting Androgen Deprivation Therapy and Risk of Castration Resistant Prostate Cancer and Metastasis: Results from the SEARCH Database. J Urol. 2020 01; 203(1):120-127. Dambal S, Howard LE, Allott EH, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Freedland SJ. PMID: 31430247.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    35. Predictors of skeletal-related events and mortality in men with metastatic, castration-resistant prostate cancer: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Cancer. 2019 11 15; 125(22):4003-4010. Tablazon IL, Howard LE, De Hoedt AM, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Freedland SJ, Williams SB. PMID: 31390061; PMCID: PMC6819222.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    36. Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality. JAMA Oncol. 2019 07 01; 5(7):975-983. Dess RT, Hartman HE, Mahal BA, Soni PD, Jackson WC, Cooperberg MR, Amling CL, Aronson WJ, Kane CJ, Terris MK, Zumsteg ZS, Butler S, Osborne JR, Morgan TM, Mehra R, Salami SS, Kishan AU, Wang C, Schaeffer EM, Roach M, Pisansky TM, Shipley WU, Freedland SJ, Sandler HM, Halabi S, Feng FY, Dignam JJ, Nguyen PL, Schipper MJ, Spratt DE. PMID: 31120534; PMCID: PMC6547116.
      View in: PubMed   Mentions: 150     Fields:    Translation:HumansCTClinical Trials
    37. Salvage Radiotherapy for Recurrent Prostate Cancer: Can the Prognostic Grade Group System Inform Treatment Timing? Clin Genitourin Cancer. 2019 10; 17(5):e930-e938. Tay KJ, Polascik TJ, Howard LE, Salama JK, Schulman AA, Chen Z, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ. PMID: 31257075.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    38. Influence of African American race on the association between preoperative biopsy grade group and adverse histopathologic features of radical prostatectomy. Cancer. 2019 09 01; 125(17):3025-3032. Aminsharifi A, Schulman A, Howard LE, Tay KJ, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ, Polascik TJ. PMID: 31042315.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    39. Validity of the National Death Index to ascertain the date and cause of death in men having undergone prostatectomy for prostate cancer. Prostate Cancer Prostatic Dis. 2019 12; 22(4):633-635. Moghanaki D, Howard LE, De Hoedt A, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Freedland SJ. PMID: 31036926; PMCID: PMC6819236.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    40. Poorly controlled diabetes increases the risk of metastases and castration-resistant prostate cancer in men undergoing radical prostatectomy: Results from the SEARCH database. Cancer. 2019 08 15; 125(16):2861-2867. Nik-Ahd F, Howard LE, Eisenberg AT, Aronson WJ, Terris MK, Cooperberg MR, Amling CL, Kane CJ, Freedland SJ. PMID: 31034601; PMCID: PMC6663572.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    41. Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis. Eur Urol. 2020 01; 77(1):3-10. Sandler KA, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Song DY, Klein EA, Stephenson AJ, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco SC, Deville C, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR, Kishan AU. PMID: 30992160; PMCID: PMC7521828.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    42. Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease. BMC Cancer. 2019 Apr 01; 19(1):291. Parikh NR, Huiza C, Patel JS, Tsai S, Kalpage N, Thein M, Pitcher S, Lee SP, Inouye WS, Jordan ML, Sanati H, Jafari L, Bennett CJ, Gin GE, Kishan AU, Reiter RE, Lewis M, Sadeghi A, Aronson WJ, Garraway IP, Rettig MB, Nickols NG. PMID: 30935383; PMCID: PMC6444674.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    43. MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer. Prostate Cancer Prostatic Dis. 2019 12; 22(4):531-538. Nickols NG, Nazarian R, Zhao SG, Tan V, Uzunangelov V, Xia Z, Baertsch R, Neeman E, Gao AC, Thomas GV, Howard L, De Hoedt AM, Stuart J, Goldstein T, Chi K, Gleave ME, Graff JN, Beer TM, Drake JM, Evans CP, Aggarwal R, Foye A, Feng FY, Small EJ, Aronson WJ, Freedland SJ, Witte ON, Huang J, Alumkal JJ, Reiter RE, Rettig MB. PMID: 30804427; PMCID: PMC6853839.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCells
    44. First-year weight loss with androgen-deprivation therapy increases risks of prostate cancer progression and prostate cancer-specific mortality: results from SEARCH. Cancer Causes Control. 2019 Mar; 30(3):259-269. Griffin K, Csizmadi I, Howard LE, Pomann GM, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Beebe-Dimmer J, Freedland SJ. PMID: 30701374; PMCID: PMC6599459.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    45. Practice patterns and outcomes of equivocal bone scans for patients with castration-resistant prostate cancer: Results from SEARCH. Asian J Urol. 2019 Jul; 6(3):242-248. Hanyok BT, Everist MM, Howard LE, De Hoedt AM, Aronson WJ, Cooperberg MR, Kane CJ, Amling CL, Terris MK, Freedland SJ. PMID: 31297315; PMCID: PMC6595156.
      View in: PubMed   Mentions: 2  
    46. Role of Host GPR120 in Mediating Dietary Omega-3 Fatty Acid Inhibition of Prostate Cancer. J Natl Cancer Inst. 2019 01 01; 111(1):52-59. Liang P, Henning SM, Guan J, Grogan T, Elashoff D, Olefsky JM, Cohen P, Aronson WJ. PMID: 30202902; PMCID: PMC6335116.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    47. Socioeconomic status, race, and long-term outcomes after radical prostatectomy in an equal access health system: Results from the SEARCH database. Urol Oncol. 2019 04; 37(4):289.e11-289.e17. Everist MM, Howard LE, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Freedland SJ. PMID: 30598238; PMCID: PMC6440810.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    48. Obesity, risk of biochemical recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database. BJU Int. 2019 07; 124(1):69-75. Freedland SJ, Branche BL, Howard LE, Hamilton RJ, Aronson WJ, Terris MK, Cooperberg MR, Amling CL, Kane CJ, SEARCH Database Study Group. PMID: 30347135; PMCID: PMC6476692.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    49. Does race predict the development of metastases in men who receive androgen-deprivation therapy for a biochemical recurrence after radical prostatectomy? Cancer. 2019 02 01; 125(3):434-441. Vidal AC, Howard LE, De Hoedt A, Kane CJ, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Lechpammer S, Flanders SC, Freedland SJ. PMID: 30427535; PMCID: PMC6340729.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    50. Statins are Associated With Increased Biochemical Recurrence After Radical Prostatectomy in Diabetic Men but no Association was Seen in Men also Taking Metformin: Results From the SEARCH Database. Clin Genitourin Cancer. 2019 Feb; 17(1):e140-e149. Aminsharifi A, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Polascik TJ, Freedland SJ. PMID: 30366879.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    51. Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2019 05; 22(2):252-260. Whitney CA, Howard LE, Freedland SJ, DeHoedt AM, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Daskivich TJ. PMID: 30279582.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    52. Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital. Int J Urol. 2018 12; 25(12):998-1004. Patel DN, Jha S, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Chapin BF, Freedland SJ. PMID: 30253446; PMCID: PMC6279517.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    53. Is Ki67 prognostic for aggressive prostate cancer? A multicenter real-world study. Biomark Med. 2018 07; 12(7):727-736. Fantony JJ, Howard LE, Csizmadi I, Armstrong AJ, Lark AL, Galet C, Aronson WJ, Freedland SJ. PMID: 29902938; PMCID: PMC6219443.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    54. Reply to the letter by Demark-Wahnefried et al. Prostate Cancer Prostatic Dis. 2018 06; 21(2):295. Aronson WJ, Henning SM. PMID: 29858594.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    55. Neutrophil, lymphocyte and platelet counts, and risk of prostate cancer outcomes in white and black men: results from the SEARCH database. Cancer Causes Control. 2018 06; 29(6):581-588. Vidal AC, Howard LE, de Hoedt A, Cooperberg MR, Kane CJ, Aronson WJ, Terris MK, Amling CL, Taioli E, Fowke JH, Freedland SJ. PMID: 29663110; PMCID: PMC5940530.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    56. Obese patients with castration-resistant prostate cancer may be at a lower risk of all-cause mortality: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int. 2018 07; 122(1):76-82. Vidal AC, Howard LE, de Hoedt A, Kane CJ, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Freedland SJ. PMID: 29521009; PMCID: PMC5997525.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    57. Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study. Int J Radiat Oncol Biol Phys. 2018 07 15; 101(4):883-888. Sandler KA, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Song DY, Klein EA, Stephenson AJ, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco SC, Deville C, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR, Kishan AU. PMID: 29976500.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    58. Radical prostatectomy and the effect of close surgical margins: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int. 2018 10; 122(4):592-598. Herforth C, Stroup SP, Chen Z, Howard LE, Freedland SJ, Moreira DM, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Kane CJ. PMID: 29473992.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    59. Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer. JAMA. 2018 03 06; 319(9):896-905. Kishan AU, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Sandler KA, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Stephenson AJ, Klein EA, Song DY, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco S, Deville C, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR. PMID: 29509865; PMCID: PMC5885899.
      View in: PubMed   Mentions: 103     Fields:    Translation:Humans
    60. First postoperative PSA is associated with outcomes in patients with node positive prostate cancer: Results from the SEARCH database. Urol Oncol. 2018 May; 36(5):239.e17-239.e25. McDonald ML, Howard LE, Aronson WJ, Terris MK, Cooperberg MR, Amling CL, Freedland SJ, Kane CJ. PMID: 29429895.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    61. Phase II prospective randomized trial of weight loss prior to radical prostatectomy. Prostate Cancer Prostatic Dis. 2018 06; 21(2):212-220. Henning SM, Galet C, Gollapudi K, Byrd JB, Liang P, Li Z, Grogan T, Elashoff D, Magyar CE, Said J, Cohen P, Aronson WJ. PMID: 29203893; PMCID: PMC5986584.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    62. Modified risk stratification grouping using standard clinical and biopsy information for patients undergoing radical prostatectomy: Results from SEARCH. Prostate. 2017 Dec; 77(16):1592-1600. Zumsteg ZS, Chen Z, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Spratt DE, Sandler HM, Freedland SJ. PMID: 28994485; PMCID: PMC5685668.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    63. Does Early Prostate Specific Antigen Doubling Time after Radical Prostatectomy, Calculated Prior to Prostate Specific Antigen Recurrence, Correlate with Prostate Cancer Outcomes? A Report from the SEARCH Database Group. J Urol. 2018 03; 199(3):713-718. Teeter AE, Griffin K, Howard LE, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ. PMID: 28870860.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    64. Timing of Prostate-specific Antigen Nadir After Radical Prostatectomy and Risk of Biochemical Recurrence. Urology. 2017 Oct; 108:129-134. Skove SL, Howard LE, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Moreira DM, Freedland SJ. PMID: 28735016; PMCID: PMC6150912.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    65. Follow-up of Prostatectomy versus Observation for Early Prostate Cancer. N Engl J Med. 2017 07 13; 377(2):132-142. Wilt TJ, Jones KM, Barry MJ, Andriole GL, Culkin D, Wheeler T, Aronson WJ, Brawer MK. PMID: 28700844.
      View in: PubMed   Mentions: 177     Fields:    Translation:Humans
    66. Biopsy Detected Gleason Pattern 5 is Associated with Recurrence, Metastasis and Mortality in a Cohort of Men with High Risk Prostate Cancer. J Urol. 2017 12; 198(6):1309-1315. Stroup SP, Moreira DM, Chen Z, Howard L, Berger JH, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Kane CJ, Freedland SJ. PMID: 28709888; PMCID: PMC6946381.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    67. Predictors of operative time during radical retropubic prostatectomy and robot-assisted laparoscopic prostatectomy. Int J Urol. 2017 08; 24(8):618-623. Simon RM, Howard LE, Moreira DM, Terris MK, Kane CJ, Aronson WJ, Amling CL, Cooperberg MR, Freedland SJ. PMID: 28697533.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    68. Validation of the 2015 prostate cancer grade groups for predicting long-term oncologic outcomes in a shared equal-access health system. Cancer. 2017 Nov 01; 123(21):4122-4129. Schulman AA, Howard LE, Tay KJ, Tsivian E, Sze C, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ, Polascik TJ. PMID: 28662291; PMCID: PMC6986737.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    69. Race and risk of metastases and survival after radical prostatectomy: Results from the SEARCH database. Cancer. 2017 Nov 01; 123(21):4199-4206. Freedland SJ, Vidal AC, Howard LE, Terris MK, Cooperberg MR, Amling CL, Kane CJ, Aronson WJ, Shared Equal Access Regional Cancer Hospital (SEARCH) Database Study Group. PMID: 28654204; PMCID: PMC5650540.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    70. Commentary on "Integrative clinical genomics of advanced prostate cancer". Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng FY, Tomlins SA, Cooney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu EY, Mostaghel EA, Cheng HH, Mulcahy H, True LD, Plymate SR, Dvinge H, Ferraldeschi R, Flohr P, Miranda S, Zafeiriou Z, Tunariu N, Mateo J, Perez-Lopez R, Demichelis F, Robinson BD, Schiffman M, Nanus DM, Tagawa ST, Sigaras A, Eng KW, Elemento O, Sboner A, Heath EI, Scher HI, Pienta KJ, Kantoff P, de Bono JS, Rubin MA, Nelson PS, Garraway LA, Sawyers CL, Chinnaiyan AM.Cell. 21 May 2015;161(5):1215-1228. Urol Oncol. 2017 08; 35(8):535. Freedland SJ, Aronson WJ. PMID: 28623072.
      View in: PubMed   Mentions: 223     Fields:    Translation:Humans
    71. Commentary on "Inherited DNA-repair gene mutations in men with metastatic prostate cancer". Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, Chinnaiyan A, Vinson J, Filipenko J, Garraway L, Taplin ME, AlDubayan S, Han GC, Beightol M, Morrissey C, Nghiem B, Cheng HH, Montgomery B, Walsh T, Casadei S, Berger M, Zhang L, Zehir A, Vijai J, Scher HI, Sawyers C, Schultz N, Kantoff PW, Solit D, Robson M, Van Allen EM, Offit K, de Bono J, Nelson PS. N Engl J Med. 2016;375(5):443-53. Urol Oncol. 2017 08; 35(8):536-537. Freedland SJ, Aronson WJ. PMID: 28623070.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    72. Characterization of a "low-risk" cohort of grade group 2 prostate cancer patients: Results from the Shared Equal Access Regional Cancer Hospital database. Int J Urol. 2017 08; 24(8):611-617. McGinley KF, Sun X, Howard LE, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ. PMID: 28589550; PMCID: PMC6986736.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    73. Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer. BJU Int. 2017 11; 120(5B):E80-E86. Howard LE, Moreira DM, De Hoedt A, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Freedland SJ. PMID: 28371163; PMCID: PMC5617753.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    74. Factors predicting skeletal-related events in patients with bone metastatic castration-resistant prostate cancer. Cancer. 2017 05 01; 123(9):1528-1535. Klaassen Z, Howard LE, de Hoedt A, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ. PMID: 28026865; PMCID: PMC5562436.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    75. Keratin 13 Is Enriched in Prostate Tubule-Initiating Cells and May Identify Primary Prostate Tumors that Metastasize to the Bone. PLoS One. 2016; 11(10):e0163232. Liu S, Cadaneanu RM, Zhang B, Huo L, Lai K, Li X, Galet C, Grogan TR, Elashoff D, Freedland SJ, Rettig M, Aronson WJ, Knudsen BS, Lewis MS, Garraway IP. PMID: 27711225; PMCID: PMC5053503.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    76. Number of Unfavorable Intermediate-Risk Factors Predicts Pathologic Upstaging and Prostate Cancer-Specific Mortality Following Radical Prostatectomy: Results From the SEARCH Database. Prostate. 2017 02; 77(2):154-163. Zumsteg ZS, Chen Z, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Spratt DE, Sandler HM, Freedland SJ. PMID: 27683213.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    77. Predicting Time From Metastasis to Overall Survival in Castration-Resistant Prostate Cancer: Results From SEARCH. Clin Genitourin Cancer. 2017 02; 15(1):60-66.e2. Moreira DM, Howard LE, Sourbeer KN, Amarasekara HS, Chow LC, Cockrell DC, Pratson CL, Hanyok BT, Aronson WJ, Kane CJ, Terris MK, Amling CL, Cooperberg MR, Freedland SJ. PMID: 27692812; PMCID: PMC5536956.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    78. In Men with Castration-Resistant Prostate Cancer, Visceral Metastases Predict Shorter Overall Survival: What Predicts Visceral Metastases? Results from the SEARCH Database. Eur Urol Focus. 2017 10; 3(4-5):480-486. Whitney CA, Howard LE, Posadas EM, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ. PMID: 28753787.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    79. Race does not predict the development of metastases in men with nonmetastatic castration-resistant prostate cancer. Cancer. 2016 Dec 15; 122(24):3848-3855. Whitney CA, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ. PMID: 27505036.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    80. Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. Eur Urol. 2017 05; 71(5):766-773. Kishan AU, Shaikh T, Wang PC, Reiter RE, Said J, Raghavan G, Nickols NG, Aronson WJ, Sadeghi A, Kamrava M, Demanes DJ, Steinberg ML, Horwitz EM, Kupelian PA, King CR. PMID: 27452951; PMCID: PMC10262972.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    81. Pathological and Biochemical Outcomes among African-American and Caucasian Men with Low Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance Candidacy. J Urol. 2016 11; 196(5):1408-1414. Leapman MS, Freedland SJ, Aronson WJ, Kane CJ, Terris MK, Walker K, Amling CL, Carroll PR, Cooperberg MR. PMID: 27352635; PMCID: PMC5542578.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    82. Effect of Dietary Omega-3 Fatty Acids on Tumor-Associated Macrophages and Prostate Cancer Progression. Prostate. 2016 10; 76(14):1293-302. Liang P, Henning SM, Schokrpur S, Wu L, Doan N, Said J, Grogan T, Elashoff D, Cohen P, Aronson WJ. PMID: 27338236; PMCID: PMC5081258.
      View in: PubMed   Mentions: 18     Fields:    Translation:AnimalsCells
    83. Predictors of Time to Metastasis in Castration-resistant Prostate Cancer. Urology. 2016 Oct; 96:171-176. Moreira DM, Howard LE, Sourbeer KN, Amarasekara HS, Chow LC, Cockrell DC, Hanyok BT, Aronson WJ, Kane CJ, Terris MK, Amling CL, Cooperberg MR, Liede A, Freedland SJ. PMID: 27318265; PMCID: PMC5536963.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    84. Variations in payment patterns for surgical care in the centers for Medicare and Medicaid Services. Surgery. 2017 02; 161(2):312-319. Bergman J, Laviana AA, Kwan L, Lerman SE, Aronson WJ, Bennett CJ, Hu JJ. PMID: 26922367.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    85. Validation of a bone scan positivity risk table in non-metastatic castration-resistant prostate cancer. BJU Int. 2016 Oct; 118(4):570-7. Freedland SJ, Howard LE, Hanyok BT, Kadiyala VK, Kuang JY, Whitney CA, Wilks FR, Kane CJ, Terris MK, Amling CL, Cooperberg MR, Aronson WJ, Moreira DM. PMID: 26762961; PMCID: PMC6986739.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    86. Racial Differences in the Association Between Preoperative Serum Cholesterol and Prostate Cancer Recurrence: Results from the SEARCH Database. Cancer Epidemiol Biomarkers Prev. 2016 Mar; 25(3):547-54. Allott EH, Howard LE, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ. PMID: 26809276; PMCID: PMC4779730.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    87. Utilization and impact of surgical technique on the performance of pelvic lymph node dissection at radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital database. Int J Urol. 2016 Mar; 23(3):241-6. McGinley KF, Sun X, Howard LE, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ. PMID: 26667212.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    88. Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database. Cancer. 2016 Jan 15; 122(2):222-9. Hanyok BT, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Posadas EM, Freedland SJ. PMID: 26484853.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    89. Do all men with pathological Gleason score 8-10 prostate cancer have poor outcomes? Results from the SEARCH database. BJU Int. 2016 08; 118(2):250-7. Fischer S, Lin D, Simon RM, Howard LE, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ, Vidal AC. PMID: 26351095.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    90. Does larger tumor volume explain the higher prostate specific antigen levels in black men with prostate cancer--Results from the SEARCH database. Cancer Epidemiol. 2015 Dec; 39(6):1066-70. Klaassen Z, Howard L, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Kane CJ, Freedland SJ. PMID: 26452418; PMCID: PMC4679602.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    91. Adverse pathology and undetectable ultrasensitive prostate-specific antigen after radical prostatectomy: is adjuvant radiation warranted? BJU Int. 2016 06; 117(6):897-903. Simon RM, Howard LE, Freedland SJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Vidal AC. PMID: 26010251.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    92. Positive surgical margins in radical prostatectomy patients do not predict long-term oncological outcomes: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) cohort. BJU Int. 2016 Feb; 117(2):244-8. Mithal P, Howard LE, Aronson WJ, Terris MK, Cooperberg MR, Kane CJ, Amling C, Freedland SJ. PMID: 26010160; PMCID: PMC4658317.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    93. Agent Orange and long-term outcomes after radical prostatectomy. Urol Oncol. 2015 Jul; 33(7):329.e1-6. Ovadia AE, Terris MK, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ, Abern MR. PMID: 25998746.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansPHPublic Health
    94. Smoking is a predictor of adverse pathological features at radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital database. Int J Urol. 2015 Jul; 22(7):658-62. Zapata DF, Howard LE, Aronson WJ, Kane CJ, Terris MK, Amling CL, Cooperberg MR, Freedland SJ. PMID: 25872110.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    95. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database. Int J Urol. 2015 Apr; 22(4):362-6. Mithal P, Howard LE, Aronson WJ, Kane CJ, Cooperberg MR, Terris MK, Amling CL, Freedland SJ. PMID: 25728968.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    96. Randomized clinical trial of brewed green and black tea in men with prostate cancer prior to prostatectomy. Prostate. 2015 Apr 01; 75(5):550-9. Henning SM, Wang P, Said JW, Huang M, Grogan T, Elashoff D, Carpenter CL, Heber D, Aronson WJ. PMID: 25545744; PMCID: PMC4334734.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCTClinical Trials
    97. Is clinical stage T2c prostate cancer an intermediate- or high-risk disease? Cancer. 2015 May 01; 121(9):1414-21. Klaassen Z, Singh AA, Howard LE, Feng Z, Trock B, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Kane CJ, Partin A, Han M, Freedland SJ. PMID: 25492369; PMCID: PMC4409453.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    98. Practice patterns and predictors of followup imaging after a negative bone scan in men with castration resistant prostate cancer: results from the SEARCH database. J Urol. 2015 Apr; 193(4):1232-8. Sourbeer KN, Howard LE, Moreira DM, Amarasekara HS, Chow LD, Cockrell DC, Hanyok BT, Pratson CL, Kane CJ, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Hernandez RK, Freedland SJ. PMID: 25463986.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    99. Serum lipid profile and risk of prostate cancer recurrence: Results from the SEARCH database. Cancer Epidemiol Biomarkers Prev. 2014 Nov; 23(11):2349-56. Allott EH, Howard LE, Cooperberg MR, Kane CJ, Aronson WJ, Terris MK, Amling CL, Freedland SJ. PMID: 25304929; PMCID: PMC4221498.
      View in: PubMed   Mentions: 69     Fields:    Translation:Humans
    100. Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int. 2014 Nov; 114(5):661-6. Allott EH, Howard LE, Cooperberg MR, Kane CJ, Aronson WJ, Terris MK, Amling CL, Freedland SJ. PMID: 24588774; PMCID: PMC4153797.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    101. The impact of pathologic staging on the long-term oncologic outcomes of patients with clinically high-risk prostate cancer. Cancer. 2014 Jun 01; 120(11):1656-62. Abern MR, Terris MK, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ. PMID: 24647966.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    102. A 60-year-old man with gross hematuria and flank pain. Urology. 2014 Jun; 83(6):1233-5. Miller ET, Aronson WJ, Bassett JC. PMID: 24231218.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    103. Association between tumor-associated macrophage infiltration, high grade prostate cancer, and biochemical recurrence after radical prostatectomy. Am J Cancer Res. 2013; 3(5):523-9. Gollapudi K, Galet C, Grogan T, Zhang H, Said JW, Huang J, Elashoff D, Freedland SJ, Rettig M, Aronson WJ. PMID: 24224130; PMCID: PMC3816972.
      View in: PubMed   Mentions: 53  
    104. Effect of a low-fat fish oil diet on proinflammatory eicosanoids and cell-cycle progression score in men undergoing radical prostatectomy. Cancer Prev Res (Phila). 2014 Jan; 7(1):97-104. Galet C, Gollapudi K, Stepanian S, Byrd JB, Henning SM, Grogan T, Elashoff D, Heber D, Said J, Cohen P, Aronson WJ. PMID: 24169960; PMCID: PMC3947245.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    105. Cigarette smoking is associated with an increased risk of biochemical disease recurrence, metastasis, castration-resistant prostate cancer, and mortality after radical prostatectomy: results from the SEARCH database. Cancer. 2014 Jan 15; 120(2):197-204. Moreira DM, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Boffetta P, Freedland SJ. PMID: 24127391; PMCID: PMC4149056.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    106. Effects of calorie restriction and IGF-1 receptor blockade on the progression of 22Rv1 prostate cancer xenografts. Int J Mol Sci. 2013 Jul 03; 14(7):13782-95. Galet C, Gray A, Said JW, Castor B, Wan J, Beltran PJ, Calzone FJ, Elashoff D, Cohen P, Aronson WJ. PMID: 23823800; PMCID: PMC3742217.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansAnimalsCells
    107. Do nomograms designed to predict biochemical recurrence (BCR) do a better job of predicting more clinically relevant prostate cancer outcomes than BCR? A report from the SEARCH database group. Urology. 2013 Jul; 82(1):53-8. Teeter AE, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ. PMID: 23806388; PMCID: PMC3774016.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    108. High serum folate is associated with reduced biochemical recurrence after radical prostatectomy: results from the SEARCH Database. Int Braz J Urol. 2013 May-Jun; 39(3):312-8; discussion 319. Moreira DM, Bañez LL, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ. PMID: 23849564.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    109. Multi-institutional validation of the CAPRA-S score to predict disease recurrence and mortality after radical prostatectomy. Eur Urol. 2014 Jun; 65(6):1171-7. Punnen S, Freedland SJ, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Carroll PR, Cooperberg MR. PMID: 23587869.
      View in: PubMed   Mentions: 53     Fields:    Translation:Humans
    110. Phenolic acid concentrations in plasma and urine from men consuming green or black tea and potential chemopreventive properties for colon cancer. Mol Nutr Food Res. 2013 Mar; 57(3):483-93. Henning SM, Wang P, Abgaryan N, Vicinanza R, de Oliveira DM, Zhang Y, Lee RP, Carpenter CL, Aronson WJ, Heber D. PMID: 23319439; PMCID: PMC3600069.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansAnimalsCells
    111. Diabetes predicts metastasis after radical prostatectomy in obese men: results from the SEARCH database. BJU Int. 2013 Jun; 111(8):E310-8. Wu C, Aronson WJ, Terris MK, Presti JC, Kane CJ, Amling CL, Freedland SJ. PMID: 23305170.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    112. Detectable prostate-specific antigen Nadir during androgen-deprivation therapy predicts adverse prostate cancer-specific outcomes: results from the SEARCH database. Eur Urol. 2014 Mar; 65(3):620-7. Keto CJ, Aronson WJ, Terris MK, Presti JC, Kane CJ, Amling CL, Freedland SJ. PMID: 23245686; PMCID: PMC3634863.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    113. Delayed radical prostatectomy for intermediate-risk prostate cancer is associated with biochemical recurrence: possible implications for active surveillance from the SEARCH database. Prostate. 2013 Mar; 73(4):409-17. Abern MR, Aronson WJ, Terris MK, Kane CJ, Presti JC, Amling CL, Freedland SJ. PMID: 22996686.
      View in: PubMed   Mentions: 42     Fields:    Translation:Humans
    114. Obesity, prostate-specific antigen nadir, and biochemical recurrence after radical prostatectomy: biology or technique? Results from the SEARCH database. Eur Urol. 2012 Nov; 62(5):910-6. Ho T, Gerber L, Aronson WJ, Terris MK, Presti JC, Kane CJ, Amling CL, Freedland SJ. PMID: 22921964; PMCID: PMC3500618.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    115. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012 Jul 19; 367(3):203-13. Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, Gingrich JR, Wei JT, Gilhooly P, Grob BM, Nsouli I, Iyer P, Cartagena R, Snider G, Roehrborn C, Sharifi R, Blank W, Pandya P, Andriole GL, Culkin D, Wheeler T, Prostate Cancer Intervention versus Observation Trial (PIVOT) Study Group. PMID: 22808955; PMCID: PMC3429335.
      View in: PubMed   Mentions: 606     Fields:    Translation:Humans
    116. Effect of a low-fat diet combined with IGF-1 receptor blockade on 22Rv1 prostate cancer xenografts. Mol Cancer Ther. 2012 Jul; 11(7):1539-46. Konijeti R, Koyama S, Gray A, Barnard RJ, Said JW, Castor B, Elashoff D, Wan J, Beltran PJ, Calzone FJ, Cohen P, Galet C, Aronson WJ. PMID: 22562985; PMCID: PMC3392522.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    117. Are repeat prostate biopsies safe? A cohort analysis from the SEARCH database. J Urol. 2012 Jun; 187(6):2056-60. Kopp RP, Stroup SP, Schroeck FR, Freedland SJ, Millard F, Terris MK, Aronson WJ, Presti JC, Amling CL, Kane CJ. PMID: 22498218; PMCID: PMC3409579.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    118. Does salvage radiation therapy change the biology of recurrent prostate cancer based on PSA doubling times? Results from the SEARCH database. Urology. 2012 May; 79(5):1105-10. Muller RL, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ. PMID: 22446345; PMCID: PMC3431014.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    119. Effect of race and socioeconomic status on surgical margins and biochemical outcomes in an equal-access health care setting: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Cancer. 2012 Oct 15; 118(20):4999-5007. Chu DI, Moreira DM, Gerber L, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ. PMID: 22415377; PMCID: PMC3376692.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    120. Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database. BJU Int. 2012 Aug; 110(4):492-8. Keto CJ, Aronson WJ, Terris MK, Presti JC, Kane CJ, Amling CL, Freedland SJ. PMID: 22094083; PMCID: PMC3343219.
      View in: PubMed   Mentions: 53     Fields:    Translation:Humans
    121. Phase II prospective randomized trial of a low-fat diet with fish oil supplementation in men undergoing radical prostatectomy. Cancer Prev Res (Phila). 2011 Dec; 4(12):2062-71. Aronson WJ, Kobayashi N, Barnard RJ, Henning S, Huang M, Jardack PM, Liu B, Gray A, Wan J, Konijeti R, Freedland SJ, Castor B, Heber D, Elashoff D, Said J, Cohen P, Galet C. PMID: 22027686; PMCID: PMC3232341.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCTClinical Trials
    122. Exclusion of the uniform tetraploid cells significantly improves specificity of the urine FISH assay. Diagn Cytopathol. 2013 Mar; 41(3):218-25. Moatamed NA, Apple SK, Bennett CJ, Aronson WJ, Klisak I, Shirley BJ, Moatamed F. PMID: 21987521.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    123. Global Igfbp1 deletion does not affect prostate cancer development in a c-Myc transgenic mouse model. J Endocrinol. 2011 Dec; 211(3):297-304. Gray A, Aronson WJ, Barnard RJ, Mehta H, Wan J, Said J, Cohen P, Galet C. PMID: 21903863; PMCID: PMC3271951.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    124. Analyzing serum-stimulated prostate cancer cell lines after low-fat, high-fiber diet and exercise intervention. Evid Based Complement Alternat Med. 2011; 2011:529053. Soliman S, Aronson WJ, Barnard RJ. PMID: 19376839; PMCID: PMC3135793.
      View in: PubMed   Mentions: 13  
    125. Does PSADT after radical prostatectomy correlate with overall survival?--a report from the SEARCH database group. Urology. 2011 Jan; 77(1):149-53. Teeter AE, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ. PMID: 21145094; PMCID: PMC3051841.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    126. Glycemic control and prostate cancer progression: results from the SEARCH database. Prostate. 2010 Oct 01; 70(14):1540-6. Kim HS, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ. PMID: 20687228; PMCID: PMC2930134.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    127. Chemoprevention of prostate cancer with lycopene in the TRAMP model. Prostate. 2010 Oct 01; 70(14):1547-54. Konijeti R, Henning S, Moro A, Sheikh A, Elashoff D, Shapiro A, Ku M, Said JW, Heber D, Cohen P, Aronson WJ. PMID: 20687227; PMCID: PMC2930120.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansAnimals
    128. Postoperative prostate-specific antigen nadir improves accuracy for predicting biochemical recurrence after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) and Duke Prostate Center databases. Int J Urol. 2010 Nov; 17(11):914-22. Moreira DM, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Sun LL, Moul JW, Freedland SJ. PMID: 20880361; PMCID: PMC3188446.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    129. A natural history of weight change in men with prostate cancer on androgen-deprivation therapy (ADT): results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int. 2011 Mar; 107(6):924-8. Kim HS, Moreira DM, Smith MR, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ. PMID: 20860651; PMCID: PMC3055926.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    130. Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer. 2010 Jul 15; 116(14):3389-98. Hamilton RJ, Banez LL, Aronson WJ, Terris MK, Platz EA, Kane CJ, Presti JC, Amling CL, Freedland SJ. PMID: 20586112; PMCID: PMC3188453.
      View in: PubMed   Mentions: 54     Fields:    Translation:Humans
    131. Green tea polyphenols and metabolites in prostatectomy tissue: implications for cancer prevention. Cancer Prev Res (Phila). 2010 Aug; 3(8):985-93. Wang P, Aronson WJ, Huang M, Zhang Y, Lee RP, Heber D, Henning SM. PMID: 20628004; PMCID: PMC3163459.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCells
    132. Outcomes after radical prostatectomy among men who are candidates for active surveillance: results from the SEARCH database. Urology. 2010 Sep; 76(3):695-700. Kane CJ, Im R, Amling CL, Presti JC, Aronson WJ, Terris MK, Freedland SJ, SEARCH Database Study Group. PMID: 20394969; PMCID: PMC2939285.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansPHPublic Health
    133. Association of cigarette smoking with interval to biochemical recurrence after radical prostatectomy: results from the SEARCH database. Urology. 2010 Nov; 76(5):1218-23. Moreira DM, Antonelli JA, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ. PMID: 20381838; PMCID: PMC3177236.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    134. Growth inhibitory effect of low fat diet on prostate cancer cells: results of a prospective, randomized dietary intervention trial in men with prostate cancer. J Urol. 2010 Jan; 183(1):345-50. Aronson WJ, Barnard RJ, Freedland SJ, Henning S, Elashoff D, Jardack PM, Cohen P, Heber D, Kobayashi N. PMID: 19914662; PMCID: PMC3089950.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansCells
    135. Diabetes and outcomes after radical prostatectomy: are results affected by obesity and race? Results from the shared equal-access regional cancer hospital database. Cancer Epidemiol Biomarkers Prev. 2010 Jan; 19(1):9-17. Jayachandran J, Aronson WJ, Terris MK, Presti JC, Amling CL, Kane CJ, Freedland SJ. PMID: 20056618; PMCID: PMC2805474.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    136. Benign prostatic hyperplasia: does lifestyle play a role? Phys Sportsmed. 2009 Dec; 37(4):141-6. Barnard RJ, Aronson WJ. PMID: 20048551.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    137. Obesity as a predictor of adverse outcome across black and white race: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer. 2009 Nov 15; 115(22):5263-71. Jayachandran J, Bañez LL, Aronson WJ, Terris MK, Presti JC, Amling CL, Kane CJ, Freedland SJ, SEARCH Database Study Group. PMID: 19670453; PMCID: PMC2783966.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    138. Re-calibration and external validation of an existing nomogram to predict aggressive recurrences after radical prostatectomy. BJU Int. 2010 Jun; 105(12):1654-9. Schroeck FR, Kattan MW, Moul JW, Aronson WJ, Presti JC, Terris MK, Kane CJ, Amling CL, Sun L, Freedland SJ. PMID: 19912203; PMCID: PMC7252932.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    139. Definition and preoperative predictors of persistently elevated prostate-specific antigen after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int. 2010 Jun; 105(11):1541-7. Moreira DM, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ. PMID: 19912191.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    140. Freedom from a detectable ultrasensitive prostate-specific antigen at two years after radical prostatectomy predicts a favorable clinical outcome: analysis of the SEARCH database. Urology. 2010 Feb; 75(2):439-44. Chang SL, Freedland SJ, Terris MK, Aronson WJ, Kane CJ, Amling CL, Presti JC. PMID: 19819536.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    141. Natural history of persistently elevated prostate specific antigen after radical prostatectomy: results from the SEARCH database. J Urol. 2009 Nov; 182(5):2250-5. Moreira DM, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ. PMID: 19758614.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    142. Estimated blood loss as a predictor of PSA recurrence after radical prostatectomy: results from the SEARCH database. BJU Int. 2010 Feb; 105(3):347-51. Lloyd JC, Bañez LL, Aronson WJ, Terris MK, Presti JC, Amling CL, Kane CJ, Freedland SJ. PMID: 19709073.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    143. Does early prostate-specific antigen doubling time (ePSADT) after radical prostatectomy, calculated using PSA values from the first detectable until the first recurrence value, correlate with standard PSADT? A report from the Shared Equal Access Regional Cancer Hospital Database Group. BJU Int. 2009 Dec; 104(11):1604-9. Teeter AE, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ. PMID: 19549124.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    144. Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy. J Urol. 2009 Aug; 182(2):491-6; discussion 496-8. Bañez LL, Sun L, Trock BJ, Han M, Partin AW, Aronson WJ, Terris MK, Presti JC, Kane CJ, Amling CL, Moul JW, Freedland SJ. PMID: 19524974.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    145. Predictors of secondary treatment following biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital database. BJU Int. 2010 Jan; 105(1):28-33. Moreira DM, Bañez LL, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ. PMID: 19522861.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    146. Validation of a nomogram to predict disease progression following salvage radiotherapy after radical prostatectomy: results from the SEARCH database. BJU Int. 2009 Nov; 104(10):1452-6. Moreira DM, Jayachandran J, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Stephenson AJ, Freedland SJ. PMID: 19466946.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    147. Dietary intervention strategies to modulate prostate cancer risk and prognosis. Curr Opin Urol. 2009 May; 19(3):263-7. Freedland SJ, Aronson WJ. PMID: 19300265.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimals
    148. Invited commentary: Lower urinary tract symptoms and inflammation--weighing the evidence. Am J Epidemiol. 2009 Jun 01; 169(11):1291-3; discussion 1294-5. Freedland SJ, Aronson WJ. PMID: 19395692.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    149. Race and time from diagnosis to radical prostatectomy: does equal access mean equal timely access to the operating room?--Results from the SEARCH database. Cancer Epidemiol Biomarkers Prev. 2009 Apr; 18(4):1208-12. Bañez LL, Terris MK, Aronson WJ, Presti JC, Kane CJ, Amling CL, Freedland SJ. PMID: 19336564; PMCID: PMC3179689.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    150. Exposure to Agent Orange is a significant predictor of prostate-specific antigen (PSA)-based recurrence and a rapid PSA doubling time after radical prostatectomy. BJU Int. 2009 May; 103(9):1168-72. Shah SR, Freedland SJ, Aronson WJ, Kane CJ, Presti JC, Amling CL, Terris MK. PMID: 19298411; PMCID: PMC3179688.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansPHPublic Health
    151. Words of wisdom. Re: Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. Shai I, Schwarzfuchs D, Henkin Y, Shahar DR, Witkow S, Greenberg I, Golan R, Fraser D, Bolotin A, Vardi H, Tangi-Rozental O, Zuk-Ramot R, Sarusi B, Brickner D, Schwartz Z, Sheiner E, Marko R, Katorza E, Thiery J, Fiedler GM, Blüher M, Stumvoll M, Stampfer MJ. Dietary Intervention Randomized Controlled Trial (DIRECT) Group. N Engl J Med 2008;359:229-41. Eur Urol. 2009 Jan; 55(1):249-50. Freedland SJ, Aronson WJ. PMID: 20050018.
      View in: PubMed   Mentions: 63     Fields:    
    152. Prostate cancer severity among low income, uninsured men. J Urol. 2009 Feb; 181(2):579-83; discussion 583-4. Miller DC, Litwin MS, Bergman J, Stepanian S, Connor SE, Kwan L, Aronson WJ. PMID: 19100580; PMCID: PMC2683346.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansPHPublic Health
    153. Do nomograms predict aggressive recurrence after radical prostatectomy more accurately than biochemical recurrence alone? BJU Int. 2009 Mar; 103(5):603-8. Schroeck FR, Aronson WJ, Presti JC, Terris MK, Kane CJ, Amling CL, Freedland SJ. PMID: 19021608; PMCID: PMC2753544.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    154. What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH database group. J Urol. 2008 Nov; 180(5):1980-4; discussion 1985. Teeter AE, Bañez LL, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ, SEARCH Database Group. PMID: 18801519; PMCID: PMC3182520.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    155. The association between prostate size and Gleason score upgrading depends on the number of biopsy cores obtained: results from the Shared Equal Access Regional Cancer Hospital Database. BJU Int. 2008 Nov; 102(9):1074-9. Turley RS, Terris MK, Kane CJ, Aronson WJ, Presti JC, Amling CL, Freedland SJ, SEARCH Database Study Group. PMID: 18778348; PMCID: PMC3186764.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    156. Pomegranate extract inhibits androgen-independent prostate cancer growth through a nuclear factor-kappaB-dependent mechanism. Mol Cancer Ther. 2008 Sep; 7(9):2662-71. Rettig MB, Heber D, An J, Seeram NP, Rao JY, Liu H, Klatte T, Belldegrun A, Moro A, Henning SM, Mo D, Aronson WJ, Pantuck A. PMID: 18790748; PMCID: PMC2858627.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansAnimalsCells
    157. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. Contemp Clin Trials. 2009 Jan; 30(1):81-7. Wilt TJ, Brawer MK, Barry MJ, Jones KM, Kwon Y, Gingrich JR, Aronson WJ, Nsouli I, Iyer P, Cartagena R, Snider G, Roehrborn C, Fox S. PMID: 18783735.
      View in: PubMed   Mentions: 62     Fields:    Translation:Humans
    158. Obesity is a significant risk factor for prostate cancer at the time of biopsy. Urology. 2008 Nov; 72(5):1102-5. Freedland SJ, Wen J, Wuerstle M, Shah A, Lai D, Moalej B, Atala C, Aronson WJ. PMID: 18722650; PMCID: PMC3179687.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    159. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases. BJU Int. 2008 Sep; 102(8):969-74. Freedland SJ, Sun L, Kane CJ, Presti JC, Terris MK, Amling CL, Moul JW, Aronson WJ. PMID: 18691175.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    160. Obesity and positive surgical margins by anatomic location after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital database. BJU Int. 2008 Sep; 102(8):964-8. SEARCH Database Study Group, Jayachandran J, Aronson WJ, Terris MK, Presti JC, Amling CL, Kane CJ, Freedland SJ. PMID: 18691176; PMCID: PMC3175752.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    161. Effect of low-fat diet on development of prostate cancer and Akt phosphorylation in the Hi-Myc transgenic mouse model. Cancer Res. 2008 Apr 15; 68(8):3066-73. Kobayashi N, Barnard RJ, Said J, Hong-Gonzalez J, Corman DM, Ku M, Doan NB, Gui D, Elashoff D, Cohen P, Aronson WJ. PMID: 18413778; PMCID: PMC2902987.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansAnimals
    162. Risk stratification for biochemical recurrence in men with positive surgical margins or extracapsular disease after radical prostatectomy: results from the SEARCH database. J Urol. 2008 May; 179(5):1791-6; discussion 1796. Jayachandran J, Bañez LL, Levy DE, Aronson WJ, Terris MK, Presti JC, Amling CL, Kane CJ, Freedland SJ, SEARCH Database Study Group. PMID: 18343426; PMCID: PMC3179686.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    163. Limitations of prostate specific antigen doubling time following biochemical recurrence after radical prostatectomy: results from the SEARCH database. J Urol. 2008 May; 179(5):1785-9; discussion 1789-90. Hamilton RJ, Aronson WJ, Terris MK, Kane CJ, Presti JC, Amling CL, Freedland SJ. PMID: 18343434; PMCID: PMC3179690.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    164. Ellagitannin-rich pomegranate extract inhibits angiogenesis in prostate cancer in vitro and in vivo. Int J Oncol. 2008 Feb; 32(2):475-80. Sartippour MR, Seeram NP, Rao JY, Moro A, Harris DM, Henning SM, Firouzi A, Rettig MB, Aronson WJ, Pantuck AJ, Heber D. PMID: 18202771.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansAnimalsCells
    165. Small transrectal ultrasound volume predicts clinically significant Gleason score upgrading after radical prostatectomy: results from the SEARCH database. J Urol. 2008 Feb; 179(2):523-7; discussion 527-8. Turley RS, Hamilton RJ, Terris MK, Kane CJ, Aronson WJ, Presti JC, Amling CL, Freedland SJ, SEARCH Database Study Group. PMID: 18076952.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    166. The effect of race/ethnicity on the accuracy of the 2001 Partin Tables for predicting pathologic stage of localized prostate cancer. Urology. 2008 Jan; 71(1):151-5. Heath EI, Kattan MW, Powell IJ, Sakr W, Brand TC, Rybicki BA, Thompson IM, Aronson WJ, Terris MK, Kane CJ, Presti JC, Amling CL, Freedland SJ. PMID: 18242385.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    167. Carbohydrate restriction, prostate cancer growth, and the insulin-like growth factor axis. Prostate. 2008 Jan 01; 68(1):11-9. Freedland SJ, Mavropoulos J, Wang A, Darshan M, Demark-Wahnefried W, Aronson WJ, Cohen P, Hwang D, Peterson B, Fields T, Pizzo SV, Isaacs WB. PMID: 17999389; PMCID: PMC3959866.
      View in: PubMed   Mentions: 72     Fields:    Translation:HumansAnimalsCells
    168. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA. 2007 Nov 21; 298(19):2275-80. Bañez LL, Hamilton RJ, Partin AW, Vollmer RT, Sun L, Rodriguez C, Wang Y, Terris MK, Aronson WJ, Presti JC, Kane CJ, Amling CL, Moul JW, Freedland SJ. PMID: 18029831.
      View in: PubMed   Mentions: 119     Fields:    Translation:Humans
    169. Race, biochemical disease recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database. Cancer. 2007 Nov 15; 110(10):2202-9. Hamilton RJ, Aronson WJ, Presti JC, Terris MK, Kane CJ, Amling CL, Freedland SJ. PMID: 17876838.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    170. Is a positive bladder neck margin truly a T4 lesion in the prostate specific antigen era? Results from the SEARCH Database. J Urol. 2008 Jan; 179(1):124-9; discussion 129. Buschemeyer WC, Hamilton RJ, Aronson WJ, Presti JC, Terris MK, Kane CJ, Amling CL, Freedland SJ. PMID: 17997433.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    171. A mechanism to explain how regular exercise might reduce the risk for clinical prostate cancer. Eur J Cancer Prev. 2007 Oct; 16(5):415-21. Barnard RJ, Leung PS, Aronson WJ, Cohen P, Golding LA. PMID: 17923812.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    172. PSA in the new millennium: a powerful predictor of prostate cancer prognosis and radical prostatectomy outcomes--results from the SEARCH database. Eur Urol. 2008 Apr; 53(4):758-64; discussion 765-6. Freedland SJ, Hotaling JM, Fitzsimons NJ, Presti JC, Kane CJ, Terris MK, Aronson WJ, Amling CL. PMID: 17868976.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    173. Pomegranate ellagitannin-derived metabolites inhibit prostate cancer growth and localize to the mouse prostate gland. J Agric Food Chem. 2007 Sep 19; 55(19):7732-7. Seeram NP, Aronson WJ, Zhang Y, Henning SM, Moro A, Lee RP, Sartippour M, Harris DM, Rettig M, Suchard MA, Pantuck AJ, Belldegrun A, Heber D. PMID: 17722872.
      View in: PubMed   Mentions: 79     Fields:    Translation:HumansAnimals
    174. Predicting unilateral prostate cancer based on biopsy features: implications for focal ablative therapy--results from the SEARCH database. J Urol. 2007 Oct; 178(4 Pt 1):1249-52. Scales CD, Presti JC, Kane CJ, Terris MK, Aronson WJ, Amling CL, Freedland SJ, SEARCH Database Study Group. PMID: 17698131.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    175. Risk stratification of men with Gleason score 7 to 10 tumors by primary and secondary Gleason score: results from the SEARCH database. Urology. 2007 Aug; 70(2):277-82. Kang DE, Fitzsimons NJ, Presti JC, Kane CJ, Terris MK, Aronson WJ, Amling CL, Freedland SJ, SEARCH Database Study Group. PMID: 17826489; PMCID: PMC3275808.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    176. Body mass index, prostate weight and transrectal ultrasound prostate volume accuracy. J Urol. 2007 Sep; 178(3 Pt 1):990-5. Sajadi KP, Terris MK, Hamilton RJ, Cullen J, Amling CL, Kane CJ, Presti JC, Aronson WJ, Freedland SJ. PMID: 17632170.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    177. Do racial differences in prostate size explain higher serum prostate-specific antigen concentrations among black men? Urology. 2007 Jun; 69(6):1138-42. Mavropoulos JC, Partin AW, Amling CL, Terris MK, Kane CJ, Aronson WJ, Presti JC, Mangold LA, Freedland SJ. PMID: 17572202; PMCID: PMC3275802.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    178. Impact of obesity on the utility of preoperative prostate-specific antigen velocity to predict for relapse after prostatectomy: a report from the SEARCH database. Urology. 2007 May; 69(5):921-6. King CR, Freedland SJ, Terris MK, Kane CJ, Amling CL, Aronson WJ, Presti JC. PMID: 17482935.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    179. Optimal timing, cutoff, and method of calculation of preoperative prostate-specific antigen velocity to predict relapse after prostatectomy: a report from SEARCH. Urology. 2007 Apr; 69(4):732-7. King CR, Freedland SJ, Terris MK, Aronson WJ, Kane CJ, Amling CL, Presti JC. PMID: 17445660.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    180. Upgrading and downgrading of prostate needle biopsy specimens: risk factors and clinical implications. Urology. 2007 Mar; 69(3):495-9. Freedland SJ, Kane CJ, Amling CL, Aronson WJ, Terris MK, Presti JC, SEARCH Database Study Group. PMID: 17382152; PMCID: PMC3080253.
      View in: PubMed   Mentions: 62     Fields:    Translation:Humans
    181. Changing nature of high risk patients undergoing radical prostatectomy. J Urol. 2007 Jan; 177(1):113-7. Kane CJ, Presti JC, Amling CL, Aronson WJ, Terris MK, Freedland SJ, SEARCH Database Study Group. PMID: 17162017.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    182. Is biopsy Gleason score independently associated with biochemical progression following radical prostatectomy after adjusting for pathological Gleason score? J Urol. 2006 Dec; 176(6 Pt 1):2453-8; discussion 2458. Fitzsimons NJ, Presti JC, Kane CJ, Terris MK, Aronson WJ, Amling CL, Freedland SJ. PMID: 17085127.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    183. Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. Cancer. 2006 Nov 15; 107(10):2384-91. Cooperberg MR, Freedland SJ, Pasta DJ, Elkin EP, Presti JC, Amling CL, Terris MK, Aronson WJ, Kane CJ, Carroll PR. PMID: 17039503.
      View in: PubMed   Mentions: 53     Fields:    Translation:Humans
    184. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10. Cancer. 2006 Sep 15; 107(6):1265-72. Bastian PJ, Gonzalgo ML, Aronson WJ, Terris MK, Kane CJ, Amling CL, Presti JC, Mangold LA, Humphreys E, Epstein JI, Partin AW, Freedland SJ. PMID: 16900523.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    185. Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2. Clin Cancer Res. 2006 Aug 01; 12(15):4662-70. Kobayashi N, Barnard RJ, Henning SM, Elashoff D, Reddy ST, Cohen P, Leung P, Hong-Gonzalez J, Freedland SJ, Said J, Gui D, Seeram NP, Popoviciu LM, Bagga D, Heber D, Glaspy JA, Aronson WJ. PMID: 16899616; PMCID: PMC3410648.
      View in: PubMed   Mentions: 73     Fields:    Translation:HumansAnimalsCells
    186. Delay of radical prostatectomy and risk of biochemical progression in men with low risk prostate cancer. J Urol. 2006 Apr; 175(4):1298-302; discussion 1302-3. Freedland SJ, Kane CJ, Amling CL, Aronson WJ, Presti JC, Terris MK, SEARCH Database Study Group. PMID: 16515984.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    187. Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. J Urol. 2006 Feb; 175(2):500-4; discussion 504. Freedland SJ, Platz EA, Presti JC, Aronson WJ, Amling CL, Kane CJ, Terris MK. PMID: 16406980.
      View in: PubMed   Mentions: 50     Fields:    Translation:Humans
    188. Racial differences in prognostic value of adult height for biochemical progression following radical prostatectomy. Clin Cancer Res. 2005 Nov 01; 11(21):7735-42. Freedland SJ, Aronson WJ, Trock B, Cohen P, Kane CJ, Amling CL, Presti JC, Terris MK, Shared Equal Access Regional Cancer Hospital Database Study Group. PMID: 16278394.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    189. Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study. J Clin Oncol. 2005 Oct 20; 23(30):7546-54. Freedland SJ, Isaacs WB, Platz EA, Terris MK, Aronson WJ, Amling CL, Presti JC, Kane CJ. PMID: 16234520.
      View in: PubMed   Mentions: 81     Fields:    Translation:Humans
    190. Intensive lifestyle changes may affect the progression of prostate cancer. J Urol. 2005 Sep; 174(3):1065-9; discussion 1069-70. Ornish D, Weidner G, Fair WR, Marlin R, Pettengill EB, Raisin CJ, Dunn-Emke S, Crutchfield L, Jacobs FN, Barnard RJ, Aronson WJ, McCormac P, McKnight DJ, Fein JD, Dnistrian AM, Weinstein J, Ngo TH, Mendell NR, Carroll PR. PMID: 16094059.
      View in: PubMed   Mentions: 132     Fields:    Translation:HumansCellsCTClinical Trials
    191. Obesity and prostate cancer. Urology. 2005 Mar; 65(3):433-9. Freedland SJ, Aronson WJ. PMID: 15780350.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    192. Preclinical models relevant to diet, exercise, and cancer risk. Recent Results Cancer Res. 2005; 166:47-61. Barnard RJ, Aronson WJ. PMID: 15648182.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    193. Biochemical outcome after radical prostatectomy among men with normal preoperative serum prostate-specific antigen levels. Cancer. 2004 Aug 15; 101(4):748-53. Freedland SJ, Aronson WJ, Kane CJ, Terris MK, Presti JC, Trock B, Amling CL. PMID: 15305405.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    194. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy. Urology. 2004 Aug; 64(2):335-40. Conde FA, Sarna L, Oka RK, Vredevoe DL, Rettig MB, Aronson WJ. PMID: 15302490.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    195. Obesity and biochemical outcome following radical prostatectomy for organ confined disease with negative surgical margins. J Urol. 2004 Aug; 172(2):520-4. Freedland SJ, Terris MK, Presti JC, Amling CL, Kane CJ, Trock B, Aronson WJ, Search Database Study Group. PMID: 15247719.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    196. Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. J Urol. 2004 Jun; 171(6 Pt 1):2260-4. Okotie OT, Aronson WJ, Wieder JA, Liao Y, Dorey F, DeKERNION JB, Freedland SJ. PMID: 15126798.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    197. Preoperative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade and serum prostate specific antigen. J Urol. 2004 Jun; 171(6 Pt 1):2215-20. Freedland SJ, Terris MK, Csathy GS, Kane CJ, Amling CL, Presti JC, Dorey F, Aronson WJ, Search Database Study Group. PMID: 15126788.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    198. Predictors of prostate-specific antigen progression among men with seminal vesicle invasion at the time of radical prostatectomy. Cancer. 2004 Apr 15; 100(8):1633-8. Freedland SJ, Aronson WJ, Presti JC, Amling CL, Terris MK, Trock B, Kane CJ. PMID: 15073850.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    199. Do younger men have better biochemical outcomes after radical prostatectomy? Urology. 2004 Mar; 63(3):518-22. Freedland SJ, Presti JC, Kane CJ, Aronson WJ, Terris MK, Dorey F, Amling CL, SEARCH Database Study Group. PMID: 15028449.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    200. Effect of isocaloric low-fat diet on prostate cancer xenograft progression to androgen independence. Cancer Res. 2004 Feb 15; 64(4):1252-4. Ngo TH, Barnard RJ, Anton T, Tran C, Elashoff D, Heber D, Freedland SJ, Aronson WJ. PMID: 14973081.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansAnimalsCells
    201. Exercise alters the IGF axis in vivo and increases p53 protein in prostate tumor cells in vitro. J Appl Physiol (1985). 2004 Feb; 96(2):450-4. Leung PS, Aronson WJ, Ngo TH, Golding LA, Barnard RJ. PMID: 14715676.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCells
    202. Examining the relationship between obesity and prostate cancer. Rev Urol. 2004; 6(2):73-81. Freedland SJ, Aronson WJ. PMID: 16985580; PMCID: PMC1550782.
      View in: PubMed   Mentions: 32  
    203. Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol. 2004 Feb 01; 22(3):446-53. Freedland SJ, Aronson WJ, Kane CJ, Presti JC, Amling CL, Elashoff D, Terris MK. PMID: 14691122.
      View in: PubMed   Mentions: 104     Fields:    Translation:Humans
    204. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Cancer. 2003 Dec 01; 98(11):2344-50. Freedland SJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Dorey F, Presti JC. PMID: 14635068.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    205. Risk factors for male osteoporosis. Urol Oncol. 2003 Sep-Oct; 21(5):380-3. Conde FA, Aronson WJ. PMID: 14670549.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    206. A low-fat diet and/or strenuous exercise alters the IGF axis in vivo and reduces prostate tumor cell growth in vitro. Prostate. 2003 Aug 01; 56(3):201-6. Barnard RJ, Ngo TH, Leung PS, Aronson WJ, Golding LA. PMID: 12772189.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansCellsCTClinical Trials
    207. Effect of isocaloric low-fat diet on human LAPC-4 prostate cancer xenografts in severe combined immunodeficient mice and the insulin-like growth factor axis. Clin Cancer Res. 2003 Jul; 9(7):2734-43. Ngo TH, Barnard RJ, Cohen P, Freedland S, Tran C, deGregorio F, Elshimali YI, Heber D, Aronson WJ. PMID: 12855654.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansAnimalsCells
    208. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database. J Urol. 2003 Jun; 169(6):2136-41. Freedland SJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Dorey F, Presti JC, SEARCH Database Study Group. PMID: 12771735.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    209. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database. J Urol. 2003 Jun; 169(6):2129-35. Freedland SJ, Presti JC, Terris MK, Kane CJ, Aronson WJ, Dorey F, Amling CL, SEARCH Database Study Group. PMID: 12771734.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    210. Insulin-like growth factor I (IGF-I) and IGF binding protein-1 modulate prostate cancer cell growth and apoptosis: possible mediators for the effects of diet and exercise on cancer cell survival. Endocrinology. 2003 Jun; 144(6):2319-24. Ngo TH, Barnard RJ, Leung PS, Cohen P, Aronson WJ. PMID: 12746292.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCells
    211. Predicting biochemical recurrence after radical prostatectomy for patients with organ-confined disease using p27 expression. Urology. 2003 Jun; 61(6):1187-92. Freedland SJ, de Gregorio F, Sacoolidge JC, Elshimali YI, Csathy GS, Elashoff DA, Reiter RE, Aronson WJ. PMID: 12809895.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    212. Should a positive surgical margin following radical prostatectomy be pathological stage T2 or T3? Results from the SEARCH database. J Urol. 2003 Jun; 169(6):2142-6. Freedland SJ, Aronson W, Presti JC, Kane CJ, Terris MK, Elashoff D, Amling CL, SEARCH Database Study Group. PMID: 12771736.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    213. Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database. Urology. 2003 Apr; 61(4):736-41. Freedland SJ, Presti JC, Amling CL, Kane CJ, Aronson WJ, Dorey F, Terris MK, SEARCH Database Study Group. PMID: 12670557.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    214. Comparison of percentage of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA recurrence after radical prostatectomy: results from the SEARCH database. Urology. 2003 Apr; 61(4):742-7. Freedland SJ, Aronson WJ, Csathy GS, Kane CJ, Amling CL, Presti JC, Dorey F, Terris MK, SEARCH Database Study Group. PMID: 12670558.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    215. Preoperative p27 status is an independent predictor of prostate specific antigen failure following radical prostatectomy. J Urol. 2003 Apr; 169(4):1325-30. Freedland SJ, deGregorio F, Sacoolidge JC, Elshimali YI, Csathy GS, Dorey F, Reiter RE, Aronson WJ. PMID: 12629353.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    216. Comparison of preoperative prostate specific antigen density and prostate specific antigen for predicting recurrence after radical prostatectomy: results from the search data base. J Urol. 2003 Mar; 169(3):969-73. Freedland SJ, Kane CJ, Presti JC, Terris MK, Amling CL, Dorey F, Aronson WJ. PMID: 12576824.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    217. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology. 2003 Feb; 61(2):365-9. Freedland SJ, Sutter ME, Dorey F, Aronson WJ. PMID: 12597949.
      View in: PubMed   Mentions: 85     Fields:    Translation:Humans
    218. Effect of diet and exercise on serum insulin, IGF-I, and IGFBP-1 levels and growth of LNCaP cells in vitro (United States). Cancer Causes Control. 2002 Dec; 13(10):929-35. Ngo TH, Barnard RJ, Tymchuk CN, Cohen P, Aronson WJ. PMID: 12588089.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCells
    219. Clinical utility of percent prostate needle biopsy tissue with cancer cutpoints to risk stratify patients before radical prostatectomy. Urology. 2002 Jul; 60(1):84-8. Freedland SJ, Csathy GS, Dorey F, Aronson WJ. PMID: 12100929.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    220. Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score. J Urol. 2002 Feb; 167(2 Pt 1):516-20. Freedland SJ, Csathy GS, Dorey F, Aronson WJ. PMID: 11792909.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    221. Role of testosterone, estradiol, and insulin in diet- and exercise-induced reductions in serum-stimulated prostate cancer cell growth in vitro. Nutr Cancer. 2002; 42(1):112-6. Tymchuk CN, Barnard RJ, Ngo TH, Aronson WJ. PMID: 12235642.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    222. Decreased growth of human prostate LNCaP tumors in SCID mice fed a low-fat, soy protein diet with isoflavones. Nutr Cancer. 1999; 35(2):130-6. Aronson WJ, Tymchuk CN, Elashoff RM, McBride WH, McLean C, Wang H, Heber D. PMID: 10693166.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimalsCells
    With one click, see people who:

    Run Clinical Trials

    See more options in the Advanced Search tab

    William's Networks
    Concepts (439)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (47)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCLA Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-3-g1ef1264b on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California